Results 11 to 20 of about 4,930 (158)

Stimulating Effect of Elvitegravir on Suicidal Erythrocyte Death [PDF]

Cellular Physiology and Biochemistry, 2016
Background/Aims: The antiviral drug Elvitegravir is used for the treatment of Human Immunodeficiency Virus (HIV) infections. The present study explored whether the drug is able to trigger eryptosis, the suicidal death of erythrocytes.
Rosi Bissinger, Abdulla Al Mamun Bhuyan, Elena Signoretto, Florian Lang   +3 more
doaj   +2 more sources

Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings [PDF]

HIV/AIDS: Research and Palliative Care, 2012
Janice Soo Fern Lee1, Alexandra Calmy1,2, Isabelle Andrieux-Meyer1, Nathan Ford1,31Médecins Sans Frontières, 2HIV/AIDS Unit, Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland; 3Centre for Infectious Disease
Lee JSF, Calmy A, Andrieux-Meyer I, Ford N   +3 more
doaj   +3 more sources

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors [PDF]

Retrovirology, 2009
Correction to Erik Serrao, Srinivas Odde, Kavya Ramkumar and Nouri Neamati: Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009, 6:25.
Neamati Nouri, Ramkumar Kavya, Odde Srinivas, Serrao Erik   +3 more
doaj   +4 more sources

Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS

HIV/AIDS: Research and Palliative Care, 2014
Krishan K PandeyInstitute for Molecular Virology, Saint Louis University Health Sciences Center, St Louis, MO, USAAbstract: Human immunodeficiency virus type 1 (HIV-1) integrase inhibitors belong to a novel class of antiretroviral drugs with high potency
Pandey KK
doaj   +1 more source

Supplementary Figure from Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m⁶A Methyltransferase METTL3

, 2022
Supplementary Figure from Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m6A Methyltransferase ...
Zi-Jia Huang (14956611), Guo-Geng Zhang (14956608), Bin Li (14956623), Long Liao (810208), Wei Yu (43094), Shu-Jun Li (9335526), Yan He (116705), Jing Yang (13969), Qing-Yu He (14956617), Can-Can Zheng (14956614), Yan Li (14956620)   +10 more
core   +8 more sources

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system. [PDF]

HIV Med
Abstract Objective Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged.
Zhang L, Chen L, Tang J, Liu X, Zheng L, Wang F, Huang X, Cao W, Li T.   +8 more
europepmc   +2 more sources

Supplementary Table from Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m⁶A Methyltransferase METTL3

, 2022
Supplementary Table from Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m6A Methyltransferase ...
Zi-Jia Huang (14956611), Guo-Geng Zhang (14956608), Bin Li (14956623), Long Liao (810208), Wei Yu (43094), Shu-Jun Li (9335526), Yan He (116705), Jing Yang (13969), Qing-Yu He (14956617), Can-Can Zheng (14956614), Yan Li (14956620)   +10 more
core   +7 more sources

Characteristics and management of low-level viraemia in people living with HIV in a resource-limited setting: A multicentre retrospective study in Greece. [PDF]

HIV Med
Abstract Objectives Low‐level viraemia (LLV) persists in some people living with HIV despite antiretroviral therapy, raising concerns about virologic failure. We assessed the characteristics, management and outcomes of LLV in Greece, where next‐generation sequencing, therapeutic drug monitoring and electronic adherence monitoring are unavailable ...
Leonidou L, Lourida G, Protopapas K, Moschopoulos CD, Zoulas D, Totsikas C, Basoulis D, Mastrogianni E, Beloukas A, Lagadinou M, Marangos M, Papastamopoulos V, Papadopoulos A, Psichogiou M.   +13 more
europepmc   +2 more sources

HIV-1 Resistance to Dolutegravir in Benin: The Need to Improve and Strengthen Therapeutic Patient Education Strategies to Achieve the Third Objective 95 of UNAIDS 95-95-95 Target. [PDF]

Case Rep Infect Dis
Benin has adopted the WHO 2019 recommendations by integrating dolutegravir into the first‐ and second‐line treatment regimen with regular monitoring of the emergence of resistance. The standard of care document has been updated, and healthcare staff have been trained on dosage, drug interactions, and the management of adverse effects.
Tchiakpe E, Diop-Ndiaye H, Osawe S, Toure-Kane C, Yessoufou A.   +4 more
europepmc   +2 more sources

Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study [PDF]

, 2020
Contains fulltext : 229127.pdf (Publisher’s version ) (Open Access)This phase-IV study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 HIV-1-positive women.
Bukkems, V.E., Burger, D.M., Garcia, C., Konopnicki, D., Schwarze-Zander, C., Lambert, J.S., Necsoi, C., Tenorio, C.H., Rockstroh, J., Colbers, A.   +9 more
core   +2 more sources